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ABSTRACT 
Methadone is one of the most popular synthetic opioids in the world with some favorable properties making it 
useful both in the treatment of moderate to severe pain and for opioid addiction. Increased use of methadone has 
resulted in an increased prevalence of its toxicity, one aspect of which is cardiotoxicity. In this paper, we review 
the effects of methadone on the heart as well as cardiac concerns in some special situations such as pregnancy 
and childhood. Methods: We searched for the terms methadone, toxicity, poisoning, cardiotoxicity, heart, 
dysrhythmia, arrhythmia, QT interval prolongation, torsade de pointes, and Electrocardiogram (ECG) in biblio-
graphical databases including TUMS digital library, PubMed, Scopus, and Google Scholar. This review includes 
relevant articles published between 2000 and 2013. The main cardiac effects of methadone include prolongation 
of QT interval and torsade de pointes. Other effects include changes in QT dispersion, pathological U waves, 
Taku-Tsubo syndrome (stress cardiomyopathy), Brugada-like syndrome, and coronary artery diseases. The aim 
of this paper is to inform physicians and health care staff about these adverse effects. Effectiveness of methadone 
in the treatment of pain and addiction should be weighed against these adverse effects and physicians should 
consider the ways to lessen such undesirable effects. This article presents some recommendations to prevent 
heart toxicity in methadone users. 
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INTRODUCTION 
Acute overdose is one of the main com-
plications of abuse and causes of mortality in 
opioid addicted patients (Afshari et al., 2007; 
Ayatollahi et al., 2011). Approximately, 
eight million people are substance abusers 
worldwide, most of whom, are from south-
east and southwest Asia (Justo et al., 2006). 
Iran has the highest rate of opioid addiction 
in the world (Karrari et al., 2012; Mehrpour, 
2012; Mehrpour and Sezavar, 2012). This 
country appears to be involved in both tradi-
tional and modern drug use and abuse prob-
lems and has an important role in the trans-
portation of opium from Afghanistan to 
western countries (Day et al., 2006; Karrari 
et al., 2013). While in western countries, al-
cohol, cannabis, methamphetamine, and her-
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oin are the most common abused drugs, in 
Iran opium remains the most commonly 
abused drug with opium poisoning and over-
dose being the major cause of drug-related 
hospital admissions (Movaghar et al., 2005; 
Ayatollahi et al., 2011; Jafari et al., 2010; 
Koushesh and Afshari, 2009; Taghaddosi-
nejad et al., 2011). 
Methadone, a synthetic opioid, was first 
produced in 1937 in Germany during world 
war II. The US Food and Drug Administra-
tion (FDA) approved it as an analgesic in 
1947 (Ehret et al., 2007; Noorzurani et al., 
2009; Shields et al., 2007; Stimmel, 2011). 
Methadone is an agonist of mu receptors 
(Izadi-Mood et al., 2008) that has been used 
as an alternative treatment in the control of 
opioid dependency since the 1960s (Justo et 
al., 2006). Methadone Maintenance Treat-
ment (MMT) is the common for methadone 
treatment in opioid addiction (Izadi-Mood et 
al., 2008) and is the best choice for treatment 
of opioid dependence (Pani et al., 2011; 
Peles et al., 2007). The use of MMT began in 
the US in 1964 when Dole and Nyswander 
first used this synthetic opioid for narcotic 
addiction (Palmiere et al., 2011) and is an 
appropriate option for patients with a history 
of long-term opioid addiction when absti-
nence and other therapies have failed (Kobek 
et al., 2009). 
At least 750000 patients are on MMT 
worldwide (Ehret et al., 2007). In America 
and Australia, about 250000 and 23300 pa-
tients are on MMT, respectively (Thanavaro 
and Thanavaro, 2011; Zador and Sunjic, 
2000). Also, methadone is the most common 
prescribed drug for opioid dependence in Ire-
land (Roy et al., 2012; Teichtahl et al., 
2004). In Europe, use of MMT ranges from 
6-22 % in the United Kingdom (UK) to 41-
86 % in Spain (Justo et al., 2006). The higher 
incidence of methadone poisoning in Iran 
may be due to MMT, which has only been 
started in recent years and has increased ac-
cess to methadone (Ayatollahi et al., 2011). 
Methadone has different applications in 
the clinics. It is highly lipid-soluble and can 
therefore be administered once daily; it has 
long elimination half-life and is metabolized 
by liver (renal function does not interfere 
with half-life), and is an antagonist of the N-
methyl-D-aspartate (NMDA) receptor caus-
ing reducing neuropathic pain (Ehret et al., 
2007). Methadone is different from other 
drugs in that it causes less stupor and does 
not interfere with mental and physical activi-
ties causing the patients to have better social 
relationships (Kobek et al., 2009). MMT has 
five main benefits: reduction in the use of il-
legal substances, decreasing viral transmis-
sion through reduced injection of drugs, de-
clining deaths due to excessive use of drugs, 
improvement in physical and mental health, 
and diminishing criminal activities (Fahey et 
al., 2003). Other important uses of metha-
done are obviating moderate to severe pain 
(Palmiere et al., 2011) and resistant cough in 
patients with lung cancer (Izadi-Mood et al., 
2008). 
Although methadone is a safe drug, over-
doses have been reported (Cruciani 2008; 
Paulozzi et al., 2009). It also causes some 
side effects on central nervous system, skin, 
gastrointestinal tract, and urogenital and 
cardiovascular systems (Izadi-Mood et al., 
2008). One of the adverse events of 
methadone is its cardiotoxicity (Kumar, 
2010). Indeed, increased QT dispersion, QT 
interval prolongation, and torsade de pointes 
(TDP) -a life-threatening arrhythmia- are all 
reported in patients treated with methadone 
(Cruciani 2008; Price et al., 2013). These 
cardiovascular side effects were so promin-
ent when a derrivative Levacetyl methadol 
(LAAM) or Orlaam (Deamer et al., 2001) 
which caused LAAM was introduced, that it 
had to be eliminated from European markets 
(Deamer et al., 2001; Guay, 2009; Kumar, 
2010). 
The goal of this paper is to review, in de-
tail, the cardiotoxic potential of methadone, 
its mechanisms and possible treatments, and 
provide recommendations for physicians and 
healthcare staff to prevent it. 
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MATERIALS AND METHODS 
We searched for the terms methadone, 
toxicity, poisoning, cardiotoxicity, heart, 
dysrhythmia, arrhythmia, QT interval pro-
longation, torsade de pointes, and electrocar-
diogram (ECG) in bibliographical databases 
including TUMS digital library, PubMed, 
Scopus, and Google Scholar. This review in-
cludes relevant articles published between 
2000 and 2013. We chose only the articles in 
this time frame because we wanted to work 
as much as possible on newer articles and al-
so we did not find any different related pa-
pers before this time. We included not only 
human studies but also animal works in our 
study.  
 
Pharmacology of methadone 
Methadone is the drug of choice for the 
treatment of opioid addiction due to its spe-
cial pharmacokinetics (Strain, 2002). It is al-
so a good alternative to morphine and other 
opiate analgesics in the treatment of severe 
chronic pain (Kumar, 2010). The average 
bio-availability of methadone (about 80 %) 
is higher than other opioids and its elimina-
tion half-life is long ranging from 7 to 65 
hours (Fredheim et al., 2008). Because of 
high solubility, 98 % of methadone that has 
reached the central compartment is quickly 
transported to tissues, especially to the liver, 
kidneys, lungs, and in small proportion, to 
the brain. Almost 1-2 % remains in the blood 
with 60-90 % bound to plasma proteins 
(mostly alpha1-acid glycoprotein) (Corkery 
et al., 2004; Ferrari et al., 2004; Gallagher 
2009; Shir et al., 2001). Methadone passes 
the placenta and is also secreted in the breast 
milk. 
Methadone hydrocholoride is a racemic 
combination of two enantiomers (R and S), 
which differ in diffusion, elimination, and ef-
fects. The R-enantiomer has 10-times the po-
tency at the opioid receptor in vitro, a longer 
elimination half-life, and a higher total vol-
ume of distribution. It is responsible for al-
most all analgesic effects of the drug (Ehret 
et al., 2007). 
Certain cytochrome P450 enzymes in 
liver or other organs metabolize methadone. 
Methadone is mainly metabolized by Cyto-
chrome P450 3A4 (CYP3A4) and (CYP2D6) 
with the latter having a secondary role 
(Pimentel and Mayo, 2008; Sticherling et al., 
2005). Expression of CYP3A4 is the main 
factor causing diversity of methadone bioa-
vailability in different people. It also partici-
pates in the metabolism of other drugs in-
cluding benzodiazepines, calcium antago-
nists, macrolides, rifampin, and anticonvul-
sants. On the other hand, some drugs includ-
ing ketoconazole, fluoxetine, and grapefruit 
juice in the large amount inhibit CYP3A4 
activity and may cause the risk of drug-drug 
interaction. In Iran, the frequency of 
CYP2D6 metabolizers is up to 12 % of the 
population; thus, we expect people in this re-
gion to be more susceptible to opioid effects 
such as dependency and sedation (Mehrpour, 
2013). 
The kidneys are the main organs in the 
excretion of methadone and its metabolites 
(15-40 % during the first 24 hours). Fecal 
excretion is responsible for 20-40 % of the 
drug elimination (Ferrari et al., 2004). In a 
retrospective review conducted on 185 pa-
tients with cancer pain to measure the clear-
ance of methadone, it was shown that a mean 
methadone clearance was 186 mL/min and a 
mean elimination half-life was 61.8 hours 
(Karir, 2002). 
Methadone is preferably orally adminis-
tered (Palmiere et al., 2011) and is available 
as an oral solution (1-2 mg/mL), tablets (5-
10 mg), dispersible tablets (40 mg), and in-
jectable solutions (10 mg/mL). Methadone, 
has also a local use in the form of mouth 
wash for the treatment of painful oral ulcers 
and in powder as an analgesic on open 
wounds (Palmiere et al., 2011). 
In order to reduce the debate of suitable 
methadone dosing, low-dose, intermediate-
dose, and high dose of methadone have been 
defined as doses < 50 mg/day, 50-100 mg/ 
day, and > 100 mg/day, respectively (Strain, 
2002). The recommended dose for the relief 
of severe pain is 2.5-10 mg every 3-4 hours. 
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This dose is 60-80 mg/day for methadone 
maintenance varying from 30 to 120 mg/ day 
(Couper et al., 2005). The treatment, toxic, 
and fatal serum concentrations of methadone 
range between 0.075 and 1.1 microgram/mL, 
0.2 and 2 microgram/mL, and 0.4 and 
2.8 microgram/mL, respectively (Kobek et 
al., 2009) and vary dramatically with de-
pendence. 
 
Cardiotoxicity 
Experimental studies have found that 
methadone can affect many cardiac function 
parameters through various mechanisms 
(Sánchez Hernández et al., 2005). Despite 
being considered to be safe, there have been 
some cases of cardiotoxicity leading to sud-
den death (Chugh et al., 2008; Cruciani, 
2008). 
 
QT prolongation 
The QT interval represents the required 
time for ventricular depolarization and re-
polarization (Spevak et al., 2012) measured 
from the beginning of QRS complex to the 
end of the T wave. This interval changes 
with heart rate and is often corrected for this 
yielding a corrected QT (QTc) (Atkinson et 
al., 2007; Wilcock and Beattie, 2009). A 
QTc less than 450 and 430 msec is normal in 
females and males, respectively (Goldenberg 
et al., 2006; Kornick et al., 2003). Drugs 
such as methadone and cocaine can cause 
QT prolongation through the direct effects 
on the resting membrane potential (Wallner 
et al., 2008). Methadone and QT prolonga-
tion is a subject of international debate 
(Krook et al., 2004; Mayet et al., 2011). This 
relation was elucidated almost four decades 
ago (Mayet et al., 2011). It has been shown 
that daily use of methadone can increase QT 
interval by 12 msec (Abramson et al., 2008; 
Krantz et al., 2005a). 
As mentioned previously, early studies 
reported a relationship between methadone 
use and QT prolongation. Several cross-
sectional studies have since confirmed this 
association (Anchersen et al., 2009); Ehret et 
al. (2006), compared drug-using patients re-
ceiving methadone with those who did not 
receive it among all patients hospitalized 
over a 5-year period in a tertiary care hospi-
tal. Of 167 methadone patients, QT prolon-
gation was detected in 16.2 %. They con-
cluded that QT prolongation was common 
among methadone maintenance patients. 
Wedam et al., 2007, compared QT interval 
effects of methadone, levomethadyl, and bu-
prenorphine in a randomized trial. Baseline 
QTc was similar in the three groups. The 
levomethadyl and methadone groups were 
significantly more likely to show QTc great-
er than 470 to 490 msec or an increase from 
baseline in QTc of greater than 60 msec. 
 
QT interval dispersion 
Methadone can increase QT dispersion in 
addition to QT interval (Hassanian-Moghad-
dam et al., 2014). QT dispersion reflects the 
variety of QT intervals in the 12-lead ECG 
and is indicative of abnormal cardiac re-
polarization (Krantz et al., 2005a; Somberg 
and Molnar, 2002). The normal range for QT 
dispersion is 30-60 msec (Krantz et al., 
2005a). 
Krantz et al., investigated the effects of 
methadone on QT interval dispersion in 118 
patients who had joined the MMT facility. 
Twelve-lead ECGs were performed at both 
baseline and 6 months after the start of 
methadone therapy. Mean baseline QT dis-
persion was 32.9 msec, which increased to 
42.4 msec after 6 months of therapy. The 
QTc increased by a similar magnitude. No 
QT dispersion value exceeded 100 msec. 
They concluded that methadone could in-
crease QT dispersion as well as QT interval 
(Krantz et al., 2005a). 
 
Torsade de pointes (Tdp) 
QT prolongation is common in patients 
on MMT; however, in patients with pro-
foundly prolonged QT (≥ 500 msec), unde-
sirable complications may occur that expose 
the patients to development of Tdp 
(Almehmi et al., 2003; Drew et al., 2010; 
Fredheim et al., 2006; Gallagher et al., 2008; 
Priori et al., 2003; Thanavaro and Thana-
EXCLI Journal 2015;14:577-600 – ISSN 1611-2156 
Received: August 25, 2014, accepted: January 14, 2015, published: May 05, 2015 
 
 
581 
varo, 2011; Walley et al., 2013). Tdp is an 
abnormal heart rhythm that causes regular 
and wide polymorphic QRS complex tachy-
cardia twisting around the iso-electric base-
line (Tdp is a French word meaning "twist-
ing of the points”). This rhythm is potentially 
fatal because it may progress to ventricular 
fibrillation and therefore should not be left 
untreated (Anchersen et al., 2010; Tüns-
meyer et al., 2012). The most common cause 
of Tdp is drug use (Roden, 2008). Dessert-
enne first described Tdp in 1966 (Chiang, 
2006; Ehret et al., 2007) and Krantz et al. 
(2002), reported the association between 
methadone and Tdp for the first time in 
2002. The increase in the dosages of the drug 
in recent years has resulted in more cases of 
this abnormal rhythm. Another possibility is 
that patients taking methadone use newer 
drugs and therefore are at risk of dangerous 
drug interactions including prolongation of 
the QT interval when they use them in com-
bination with their methadone. 
Methadone inhibits the Human Ether-a-
go-go Related Gene (hERG) and causes QTc 
prolongation and development of Tdp (Eap 
et al., 2007; Esfahani et al., 2012; Sekine et 
al., 2007; Zünkler and Wos-Maganga, 2010). 
hERG, first identified in 1994, is located on 
chromosome 7 and codes for the potassium 
ion channel which intercedes repolarization 
of the cardiac action potential (Parikh et al., 
2011). This gene is expressed in multiple tis-
sues and cells including neural, smooth mus-
cle, and tumor cells. However, it is most 
highly expressed in the heart (Sanguinetti 
and Tristani-Firouzi, 2006; Smith et al., 
2002). 
The action potential of human ventricular 
myocytes can be divided into five distinct 
phases. Inward sodium current triggers a rap-
id membrane depolarization (phase 0). Re-
polarization occurs in three phases; phase 1 
which proceeds rapidly and lasts a few milli-
seconds; phase 2 called the plateau which is 
a prolonged because the K+ currents activat-
ed during this phase are slow to activate and 
have a reduced conductance at positive trans-
membrane potentials; phase 3 in which the 
action potential terminates, and phase 4 in 
which the membrane returns to its resting 
level. The most important component of 
phase 3 is the rapid delayed rectifier K+ cur-
rent (IKr) conducted by hERG channels 
(Sanguinetti and Tristani-Firouzi, 2006). 
hERG is highly susceptible to pharmaco-
logical blockade (Sanguinetti and Mitcheson 
2005). Methadone blocks the hERG channels 
at concentrations close to those clinically 
achieved (Chugh et al., 2008). This blockage 
in turn prolongs the end part of cardiac ac-
tion potential and finally reprieves repolari-
zation represented as QTc interval prolonga-
tion (Esfahani et al., 2012; Fonseca et al., 
2009; Hassnain-Moghaddam et al., 2013). 
Methadone’s R-isomer inhibits the hERG 
channel less than the S-isomer (Lin et al., 
2008). Methadone can cause QT prolonga-
tion and Tdp with other mechanisms, as 
well, including producing negative chrono-
tropic effects via Ca++ channel antagonism 
and anti-cholinesterase effect. The bradycar-
dia induced by these mechanisms makes the 
patient more susceptible to Tdp (Esfahani et 
al., 2012). Accepted risk factors for QT pro-
longation and Tdp are low K+, Mg++, or Ca++ 
concentrations, diabetes mellitus, thyroid or 
pituitary insufficiency, cardiomyopathy, re-
cent myocardial infarction (MI), sinus brad-
ycardia, certain drugs, toxins (organophos-
phates, insecticides, and heavy metals), fe-
male gender, older age, subarachnoid hemor-
rhage, starvation, genetic susceptibility, obe-
sity, alcoholism, and cirrhosis (Bednar et al., 
2001; Gupta et al., 2007; John et al., 2010; 
Kobek et al., 2009; Laqueille et al., 2012; 
Pasquier et al., 2012; Raschi et al., 2009; 
Schmidt, 2005; Vieweg et al., 2013; Viskin 
et al., 2003). 
Patients on MMT often receive concomi-
tant medications for psychiatric disorders 
and infections such as Human Immunodefi-
ciency Virus (HIV) which can raise the risk 
of drug-drug interactions (Lüthi et al., 2007). 
In methadone users, drug-drug interaction 
results in TdP via a pharmacodynamic com-
bined effect and causing an alteration of me-
tabolism. Some medications can cause QTc 
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prolongation per se (including amiodarone, 
chloroquine, clarithromycin, erythromycin, 
haloperidol, lithium, sotalol, terfenadine, and 
venlafaxine as well as grapefruit juice). 
They, when given with methadone, may in-
crease the risk of development of TdP. 
Among them are some commonly used med-
ications such as amiodarone, chlorproma-
zine, cisapride, clarithromycin, droperidol, 
erythromycin, haloperidol, pentamidine, pi-
mozide, procainamide, quinidine, sotalol, 
thioridazine, quinolones, and antifungals. 
With regard to the pharmacokinetics, metha-
done is mainly metabolized by CYP3A4 en-
zyme and to a lesser extent by CYP2B6 and 
CYP 2D6. Induction or inhibition of these 
enzymes by any means including certain 
drugs can increase or decrease the serum 
concentrations of methadone. HIV antivirals 
(e.g., indinavir, nelfinavir, and ritonavir), an-
tibiotics and antifungals such as clarithromy-
cin, itraconazole, and ketoconazole strongly 
inhibit CYP3A4 while efavirenz induces it 
(Prosser et al., 2008). 
Nair et al. (2008) introduced a 56-year-
old man receiving methadone brought to 
their emergency department because Tdp de-
veloped after using ciprofloxacin in whom 
CYP1A and CYP3A enzymes likely caused 
a pharmacokinetic reaction. Sánchez Hernán-
dez et al. (2005) reported four cases of Tdp 
during methadone treatment all of whom 
were on MMT. Three of them were HIV-
infected and one received antiretroviral ther-
apy. Two patients had low serum potassium 
concentrations. In fact, these patients had 
some associated risk factors that caused QT 
interval prolongation. Justo and colleagues 
(2006) reviewed all the publications on 
methadone-associated Tdp in addicted pa-
tients to identify the situations leading to this 
complication. All patients had at least one 
risk factor for Tdp including high-dose 
methadone, concomitant use of agents that 
increased serum methadone concentrations, 
HIV infection, hypokalemia, female gender, 
liver cirrhosis, or renal failure. Kuryshev and 
associates (2010) evaluated the cardiac risk 
in co-administration of methadone and diaz-
epam. They found that diazepam alone did 
not prolong the QT interval; but, its concom-
itant use with methadone interacted with Na+ 
channels and caused hERG K+ channel 
block. Winton and Twilla (2013) reported a 
47-year-old addicted man who was on meth-
adone and azithromycin for an upper respira-
tory tract infection and experienced a fatal 
arrhythmia. Schmittner et al. (2009) evaluat-
ed the ECG effects of co-administration of 
lofexidine and methadone in 14 participants 
dependant to opioids. There were significant 
changes in four ECG parameters; decreased 
heart rate and increased PR, QRS complex, 
and QT intervals. In three participants, QTc 
prolongation was clinically significant (it in-
creased by > 40 msec from baseline). 
Reinhold et al. (2009) reported a 57-year-
old man with comorbid conditions who de-
veloped Tdp after use of methadone and 
voriconazole. The probable cause was 
voriconazole-inhibited methadone metabo-
lism via cytochrome P450 isoenzymes 
(CYP2B6). Krantz and colleagues (2005b) 
introduced a patient on MMT who developed 
syncope due to Tdp hours after cocaine use. 
They found that cocaine and methadone pro-
longed QT interval via the same mechanism. 
 
Methadone dose dependency in QT  
prolongation and Tdp 
Ideal methadone dosage in treatment of 
opioid dependence is a matter of debate 
(Liao et al., 2013). Several large studies have 
been performed to evaluate the relationship 
between the dose of methadone and QTc 
prolongation. Some have reported a direct re-
lationship (Table 1), while others could not 
find such an association (Table 2) (Krantz et 
al., 2005a). There are several case reports 
and data on methadone-induced QT prolon-
gation in a dose-dependent manner that have 
caused considerable concern for practitioners 
in addiction medicine (Butler et al., 2011). 
Oral recommended doses range from 60 to 
100 mg per day. It has been shown that use 
of a mean dose of 100 mg or more of metha-
done leads to significant dose-dependent 
QTc prolongation in these patients (Chang et 
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Table 1: Positive dose-response relationship between methadone and cardiotoxicity 
Authors Study type Method Findings Considerations 
Krantz et al. 
(2003) 
Retrospec-
tive case se-
ries analysis 
QTc intervals were calculated for each 
patient. The relationship between daily 
methadone dose and QTc interval was 
assessed and adjusted for clinical charac-
teristics that might have independently 
prolonged cardiac repolarization. 
Multiple linear regression indicated that 
only the daily methadone dose was pre-
dictive of the QTc interval. 
All other variables examined such as age, 
sex, presence of hypokalemia or structur-
al heart disease, and presence of QT-
prolonging drugs were not predictive of 
the QTc interval (P=0.28). 
Routhier et 
al. (2007) 
Case report Presents a 52-year-old HIV-positive 
woman without underlying cardiac dis-
ease who developed QTc prolongation 
and Tdp secondary to high dose metha-
done therapy. 
This case report suggests the ability of 
methadone to induce QTc prolongation 
and Tdp in an apparent dose-dependent 
manner. 
There is a confluence of potential factors 
including underlying cardiac, hepatic, 
electrolyte abnormalities or other medica-
tions that may contribute to development 
of dysrhythmia. 
Walker et al. 
(2003) 
Case report Three patients who developed Tdp while 
receiving high dosages of oral methadone 
(> 600 mg/day) are presented. 
Until further evidence is available, it may 
be prudent to be vigilant for arrhythmias 
when high dosages of methadone are 
used especially in patients on other drugs 
that interact with the CYP3A4 isoenzyme 
system. 
In all of the cases, drug interactions in-
volving methadone and CYP3A4 isoen-
zyme system were possible. 
Ehret et al. 
(2006) 
A systematic 
retrospective 
study 
Comparing active or former intravenous 
drug users receiving methadone and 
those not receiving methadone among all 
patients hospitalized over a 5-year period 
in a tertiary care hospital. 
In 167 patients, the prevalence of QTc 
prolongation to 0.50 second or longer was 
16.2 % compared with 0 % in 80 control 
subjects. Six patients (3.6 %) in the meth-
adone group presented Tdp. QTc length 
was weakly but significantly associated 
with methadone daily dose. 
Methadone dose, presence of CYP3A4 
inhibitors, potassium concentration, and 
liver function contribute to QT prolonga-
tion. 
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Authors Study type Method Findings Considerations 
Cruciani et 
al. (2005) 
Cross-
sectional 
study 
Adult patients receiving oral methadone 
(20 mg/day > 2 weeks) were recruited 
from inpatient medical, psychiatric, and 
Hospice units and an outpatient pain 
practice. 
Patients were queried about medical his-
tory and methadone treatment. Serum 
concentrations of electrolytes known to af-
fect the QTc duration (potassium, magne-
sium, and calcium) were measured. QT 
interval was measured manually by the 
same investigator. 
Median methadone dose was 110 mg/day 
(20-1200 mg/day) for a median of 12.5 
months (1-444 months). Median QTc in-
terval was 428 msec (396-494 msec). 
Multivariate analysis was done. A signifi-
cant two-way interaction was found for 
dose and treatment duration; specifically, 
QTc was related to both higher metha-
done dose and shorter methadone treat-
ment duration. 
Seven patients had a previous history of 
structural heart disease; 25 patients were 
currently taking drugs (except for metha-
done) which have been cited as possible 
causes of QTc prolongation and 26 were 
taking drugs which are associated with 
Tdp. Thirty patients were taking drugs 
which might increase methadone serum 
concentration via pharmacokinetic inter-
actions. 
In contrast to previous studies, which 
found females to be at higher risk, this ar-
ticle indicates that the risk of methadone-
induced QTc prolongation may be greater 
in males. 
Martel et al. 
(2005) 
Prospective 
study 
Patients admitted to the division of sub-
stance abuse of Albert Einstein College of 
Medicine were recruited. Criteria for ad-
mission were opioid addiction for ≥ 1 year, 
age > 18 years, and ≥ 1 previous attempt 
at supervised ambulatory detoxification. 
All patients were initiated on oral metha-
done 30 mg with subsequent 10-mg in-
cremental increases. In addition to base-
line ECG, follow-up tracings were repeat-
ed after 6 and 12 months. 
Mean QTc increased by 12.4 ± 23 msec 
at 6 months, by 10.7 ± 30 msec at 12 
months, and the QTc change from base-
line to 12 months correlated with the 
trough and peak serum methadone con-
centrations. 
We observed a positive correlation be-
tween serum methadone concentration 
and the magnitude of QTc interval 
change. 
Variables associated with a longer QTc 
interval at baseline were older age,  
female gender (women vs men, 426 vs 
414 msec), self-reported cardiac disease 
(434 vs 416 msec,), use of antidepres-
sants (430 vs 418 msec), calcium antag-
onists (432 vs 417 msec), hepatitis C in-
fection (423 vs 413 msec), and HIV infec-
tion (423 vs 417 msec). 
In univariate analysis, only the methadone 
dose was significantly associated with the 
magnitude of the QTc increase from 
baseline at 6 months. 
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Authors Study type Method Findings Considerations 
Thanavaro 
and  
Thanavaro 
(2011) 
Case report A patient on MMT for heroin addiction re-
ferred with dizziness and near-syncope. 
He was taking a relatively high dose of 
methadone (110 mg/day) but was not tak-
ing any concomitant cytochrome P450 in-
hibitor or QT-prolonging drugs. 
The corrected QT interval became shorter 
but remained profoundly prolonged until 
methadone was substituted with bupren-
orphine. 
In the presence of QTc prolongation, 
methadone dose should be adjusted and 
the ECG should be repeated. 
Although QTc prolongation occurs more 
frequently in patients taking high daily 
doses or those with recently increased 
dosages, other factors may contribute to 
methadone-induced QTc prolongation. 
Laboratory studies revealed anemia, 
hypokalemia (2.5 meq/L), and hypomag-
nesemia (1.5 mg/dL). 
 
 
 
Table 2: Negative dose-response relationship between methadone and cardiotoxicity 
Authors Study type Method Results Considerations 
Maremmani 
et al. (2004) 
Prospective 
study 
Basal ECG recordings were carried out 
in 83 former heroin addicts on long-term 
successful MMT for at least 6 months 
(dosages ranging between 10 and 600 
mg/day), while no other known QT-
prolonging agent was being adminis-
tered. 
83 % of the subjects had a more pro-
longed QT interval than the reference 
values for persons of the same sex and 
age. Only 2 patients displayed a QTc in-
terval of >500 msec. No correlation 
emerged between QTc values and meth-
adone dosages. 
Patients did not show electrolyte imbal-
ance or altered nutritional states, nor were 
they taking medications accountable for 
as possible causes of acquired long QT 
syndrome (LQTS). 
Peles et al. 
(2007) 
Cross-
sectional 
study 
153 patients of whom 151 received high-
dose methadone for at least 2 weeks 
were studied. ECG was done at the time 
when blood was drawn for determination 
of serum methadone concentrations 
about 24 hours after the last oral metha-
done dose. Corrected-QT intervals (QTc) 
were calculated using the Bazett’s formu-
la. 
Of 138 patients studied, 98 (71 %) were 
male. Mean QTc interval was 
418.3 ± 32.8 msec. Mean methadone 
dose was 170.9 ± 50.3 mg/day and mean 
serum methadone concentration was 
708.2 ± 363.1 ng/ml. Methadone dose 
and serum concentrations did not corre-
late with QTc. 
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Authors Study type Method Results Considerations 
Huh and 
Park (2010) 
Retrospec-
tive study 
A total of 130 patients were included, with 
90 patients in the methadone group and 
40 patients in the control group. For each 
ECG, heart rate, QT interval and correct-
ed QT (QTc) interval were recorded. The 
patient demographics, methadone dose 
and serum concentration, duration of 
methadone use and past medical history 
were collected. 
QTc interval was significantly longer in the 
treatment group than in the control group 
(443 ± 30.0 msec versus 408 ± 28.0 msec 
and more patients in the treatment group 
had a QTc interval greater than 450 msec 
(36.7 % versus 7.5 %). QTc interval was 
not associated with methadone dose, se-
rum concentration or duration of treat-
ment. Methadone use is associated with 
prolonged QTc intervals, even at low dos-
es (less than 80 mg/day). 
QTc interval was greater among females, 
shorter patients and those taking anti-  
depressants. 
Pearson and 
Woosley 
(2005) 
Retrieval and 
retrospective 
study 
To review and analyze adverse events 
(QT prolongation and TdP) reported to the 
Food and Drug Administration (FDA) to 
determine the patient characteristics, 
dosages of methadone, and outcomes of 
methadone-treated patients. 
In 5503 reports of adverse events associ-
ated with methadone, 43 (0.78 %) had 
TdP and 16 (0.29 %) QT prolongation. 
Doses were reported in 42/59 (71 %) of 
cases; mean dose was 410 ± 349 mg/day 
(29 to 1680). Dosages for 10 of the 42 
cases (29 %) were within the recom-
mended range for MMT, 60-100 mg/day. 
Female gender, interacting medications, 
hypokalemia, hypomagnesemia, structur-
al heart disease, and risk factors previ-
ously identified with other drugs known to 
cause TdP were found in 44 (75 %)    
cases. 
Roy et al. 
(2012) 
Cross-
sectional 
study 
Investigate the frequency of QTc prolon-
gation in a MMT population and to exam-
ine potential association between QTc in-
terval and methadone dose as well as 
concurrent use of opiates, cocaine, and 
benzodiazepines. 
Mean methadone dose was 80.4 ± 
27.5 mg. Mean QTc was 420.9 ± 
21.1 msec (368 to 495 msec). Patients 
with positive toxicology screen for opiates 
were receiving significantly lower doses of 
methadone (77.8 ± 23.5 mg versus 85.0 ± 
21.4 mg). No association was noted be-
tween QTc interval prolongation and 
presence of urine cocaine metabolites. 
Drug-induced QTc interval prolongation is 
evident (ranging from 8.8 to 11.1 % de-
pending on definition applied) in patients 
receiving relatively low daily doses of 
methadone, with no evidence of a dose–
response relationship. 
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al., 2012). Krantz et al. (2003), investigated 
the relationship between the daily dose of 
methadone and QTc interval in methadone-
treated patients who developed Tdp. They 
concluded that daily methadone dose corre-
lated positively with the QTc interval. 
Routhier and associates (2007) presented a 
52-year-old woman without any underlying 
cardiac disease who developed QTc prolon-
gation and Tdp secondary to high-dose 
methadone therapy. This case report sug-
gested that methadone induced QTc prolon-
gation and Tdp in a dose-dependent manner. 
Walker and associates (2003) published a re-
port of three cases of Tdp in patients on daily 
doses of methadone exceeding 600 mg, two 
of whom, presented with syncope and one 
with respiratory distress. Each of the three 
was on other medications that inhibited the 
metabolism of methadone. Extra caution 
should be given for arrhythmias when high 
dosages of methadone (> 600 mg/day) are 
used, especially in patients on other drugs 
that can interact with the CYP3A4 isoen-
zyme system. Ehret et al. (2006) investigated 
the frequency of QT prolongation in MMT 
patients hospitalized in a tertiary center and 
identified associated risk factors. Methadone 
dose, CYP 3A4 inhibitors, potassium con-
centration, and liver function contributed to 
QT prolongation and QTc length was weakly 
but significantly associated with methadone 
daily dose. In the study by Cruciani and col-
leagues (2005), the median methadone dose 
was 110 mg/day. Significant dose-response 
was observed in males on methadone for less 
than 12 months. Martell and assistants 
(2005) carried out a study on 160 patients, 
all of whom were initiated on 30-mg oral 
methadone with subsequent 10-mg incre-
mental increases. They observed that there 
was a positive correlation between serum 
methadone concentration and the prolonga-
tion of QTc interval. Thanavaro and Tha-
navaro (2011), reported a case of methadone-
induced Tdp who was on high dose of the 
drug (110 mg/day) without using any con-
comitant medications. They concluded that 
methadone dose should be adjusted or the 
drug should be switched to an alternative one 
and ECG should be repeated in case of QTc 
prolongation. Although several studies indi-
cated an association between methadone 
dose and QTc interval, other investigations 
did not detect such effect (Krantz et al., 
2005a). QT interval prolongation has been 
detected with daily doses below 65 mg, as 
well (Huh and Park, 2010). 
Maremmani et al. (2004) evaluated ab-
normal QTc interval in 83 heroin addicts 
who were on long-term MMT and received 
methadone dosages between 10-600 mg/day. 
Almost 83 % of them had QT prolongation 
more than the reference values. No correla-
tion existed between QT prolongation and 
methadone dosages. Peles and associates 
(2007) studied 138 patients on MMT with 
methadone dose of 40-290 mg/day. An ECG 
was done and a serum methadone concentra-
tion was determined about 24 hours after the 
last oral methadone dose. It was shown that 
methadone dose and serum concentrations 
did not correlate with QTc.  
Huh and Park (2010) conducted a study 
on 130 patients with 90 patients in the meth-
adone and 40 patients in the control group. 
Heart rate, QT interval, and QTc were rec-
orded. The patients’ demographics, metha-
done dose and serum concentration, duration 
of methadone use, and past medical history 
were collected. QTc interval was significant-
ly longer in the methadone group. QTc inter-
val was not associated with methadone dose 
(P = 0.9) and serum concentration or dura-
tion of treatment. Pearson and Woosley 
(2005) reviewed and analyzed adverse events 
(QT prolongation and Tdp reported to FDA 
from 1969 to 2002) to determine the pa-
tients’ characteristics, dosages of methadone, 
and outcomes of methadone-treated patients. 
Analysis of the cases showed that QT pro-
longation and Tdp could occur over a wide 
range of dosages even those recommended 
for treatment of addiction. Roy and col-
leagues (2012) evaluated the correlation be-
tween QT interval and methadone dose. 
Mean methadone dose was 80.4 ± 27.5 mg in 
their study. They concluded that prolonga-
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tion of QT interval was seen even in patients 
receiving low doses of methadone without 
any dose-response relationship. 
No cut-off level for safe dose has been 
identified. Although some studies have de-
tected positive association between metha-
done dose and QTc prolongation, the rela-
tionship is usually stronger with additional 
factors such as gender, duration of treatment, 
and concomitant drug use (Huh and Park, 
2010). 
 
U-waves 
Methadone can cause pathological U 
waves (larger than the T wave) and impend-
ing Tdp (John et al., 2010). Drug-induced or 
prolonged QT syndromes can create U 
waves. In a study on the effects of metha-
done and buprenorphine on ECG, methadone 
subjects were significantly more likely to 
have U waves (Athanasos et al., 2008). 
 
Ventricular bigeminy 
Ventricular bigeminy may be due to dif-
ferent mechanisms involving a disturbance 
of impulse form/conduction or both (Lan-
gendorf et al., 1955). Scholler et al. (2011) 
demonstrated ventricular bigeminy in a Cau-
casian woman with concomitant administra-
tion of methadone, voriconazole, and esome-
prazole. She had high plasma concentrations 
of voriconazole and methadone. It was con-
cluded that a pharmacokinetic interaction be-
tween methadone and voriconazole was rein-
forced by the addition of esomeprazole. 
 
Tako-Tsubo Syndrome 
Stress cardiomyopathy (Tako-Tsubo 
syndrome) is defined as left ventricular func-
tional and ECG changes that mimic acute 
myocardial infarction without any evidence 
of involvement of coronary arteries. It is 
more common in postmenopausal women 
and an acute medical illness or emotion-
al/physical stress may typically trigger this 
syndrome (Lemesle et al., 2010; Saiful et al., 
2010). It has been demonstrated that huge re-
lease of catecholamines (maybe due to opi-
oid withdrawal) may be responsible for de-
velopment of this cardiomyopathy. Only two 
cases of Taku-Tsubo syndrome have been 
reported in relation with acute opioid with-
drawal. Lemesle et al. (2010), reported the 
first case as a result of methadone withdraw-
al secondary to drug-drug interaction. 
Brugada-like syndrome 
Brugada-like syndrome is another condi-
tion in methadone users predisposing the pa-
tients to life-threatening ventricular tachy-
cardia and sudden cardiac death. The disease 
is due to a mutation in the cardiac sodium 
channel SCNSA gene in one-fourth of the 
cases. Although the patients may have nor-
mal ECGs, coved-type ST elevation in pre-
cordial leads V1–V3 is characteristic of the 
disease. Agents causing Brugada-like ECG 
include fever, cocaine and methadone, sodi-
um channel blockers (e.g. propafenone, pro-
cainamide, flecainide, bupivacaine, lido-
caine, and tricyclic antidepressants), propo-
fol, and electrolyte imbalances (Deamer et 
al., 2001). Srivatsa and colleagues (2005) re-
ported a case of consecutive appearance of 
Brugada and long QT patterns on ECG in a 
patient receiving methadone. Junttila et al 
conducted a multi-center observational trial 
on 47 patients presenting with typical Bru-
gada-like ECGs during an acute medical 
event, 16, 26, and 5 cases were due to febrile 
episodes, drugs, and electrolyte imbalances, 
respectively. Fifty-one percent had severe ar-
rhythmias with 38 % leading to sudden car-
diac death and 6 % developing ventricular 
tachycardia and syncope. One of the victims 
of sudden cardiac death was receiving meth-
adone (Junttila et al., 2008). 
 
Methadone and coronary artery disease 
Cardiovascular diseases are the most 
common causes of death in both genders 
(Kazemi, 2012; Kazemi et al., 2011) and 
have been noticed to lead to morbidity and 
mortality in MMT clinics. Although long-
term methadone exposure may relieve the fa-
tal outcomes of coronary diseases (Marmor 
et al., 2004; Patane et al., 2007; Safaei, 
2008), opiate-related ischemia has been de-
scribed in some cases. Backmund and asso-
EXCLI Journal 2015;14:577-600 – ISSN 1611-2156 
Received: August 25, 2014, accepted: January 14, 2015, published: May 05, 2015 
 
 
589 
ciates presented a 22-year-old addicted man 
who suffered myocardial infarction after 
concomitant use of methadone and dihydro-
codeine (Backmund et al., 2001). Patane and 
assistants (2007) presented a case of acute 
myocardial infarction in a chronic metha-
done user after aspirin use (due to the para-
doxical activation of major platelet receptors 
after administration of aspirin). 
 
Methadone and hemodynamic effects 
The cardiovascular toxicity of opioids 
causes significant morbidity and mortality in 
overdose; but, the hemodynamic effects of 
opioids reported in animal and human stud-
ies are contradictory (Afshari et al., 2007). 
Afshari et al. (2007) performed a prospective 
observational study of patients admitted to 
hospital following an overdose of metha-
done, dihydrocodeine, or low-dose parace-
tamol (10 each). They observed that dihy-
drocodeine and methadone significantly re-
duced peripheral and aortic systolic, mean 
and end systolic pressures. Both significantly 
decreased peripheral pulse pressure, but only 
methadone decreased aortic blood pressure. 
Dihydrocodeine reduced systemic and aortic 
diastolic blood pressure, an effect not in-
duced by methadone. Methadone reduced 
peripheral pulse pressure. Augmentation in-
dex and heart rate, however, did not change. 
Both opioids decreased arterial oxygen satu-
ration. It was suggested that dihydrocodeine 
and methadone had a significant effect on 
central and peripheral hemodynamic when 
overdosed. Anderson and Alvarado (2003) 
assessed acute hemodynamic effects of in-
travenous methadone in 21 patients all of 
whom were scheduled for cardiac surgery. 
They found that there were no significant 
changes in any hemodynamic parameter at 
any time point. This study indicates that no 
adverse hemodynamic effects accompany a 
20-mg intravenous bolus of methadone. 
 
Use of methadone in pregnancy 
Opioid dependence is a major public 
health problem during pregnancy. A recent 
study showed that 2.6 % of pregnant women 
in the United States had positive opioid tests 
at time of admission for delivery. It is esti-
mated that in Europe 30000 opioid-addicted 
women become pregnant annually (Schmid 
et al., 2010). 
Methadone is the routine substitution 
therapy for heroin-addicted pregnant women 
(Navaneethakrishnan et al., 2006; Burns et 
al., 2010). It easily crosses the placenta and 
the final concentration of methadone in the 
umbilical cord is one-fourth of that in mater-
nal serum (Schmid et al., 2010). Pregnant 
women on MMT have better prenatal care in 
comparison with the untreated women 
(Ramirez-Cacho et al., 2006), which confers 
higher birth weights and less obstetric com-
plications, preterm births, and neonatal mor-
bidity. Despite these benefits, common 
harmful perinatal complications have also 
been reported in methadone-exposed preg-
nant women (Cleary et al., 2012). Metha-
done use by mother changes fetal heart rate 
(FHR) patterns; for example, reduces the 
baseline heart rate and variability and in-
creases the possibility of a non-reactive non-
stress test (Jansson et al., 2005; Leeman et 
al., 2011). Ramirez-Cacho (2006) and col-
leagues compared intrapartum FHR tracings 
from 56 mothers in their 36th gestational age 
and on MMT with a healthy control group 
matched for maternal age, parity, gestational 
age, and ethnicity. It was concluded that 
chronic maternal methadone treatment af-
fected intrapartum FHR patterns by reducing 
the variability, baseline, and proportion of 
accelerations during the first stage. Schmid 
and colleagues (2010) evaluated the FHR by 
Doppler ultrasound between 11+0 and 13+6 
gestational weeks in methadone-using moth-
ers and a healthy control group. They con-
cluded that in opioid-dependent mothers’ fe-
tuses a decreased FHR could be observed in 
that time period. 
 
Use of methadone in infancy 
Drug dependence is dangerous in infan-
cy. Babies of opioid-dependent mothers have 
a higher risk of mortality in their first year of 
life (Burns et al., 2010). Occurrence of sud-
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den infant death syndrome has also been re-
ported in newborns of mothers on MMT. 
Although there is transient benign increase in 
QT interval up to 500 msec in healthy new-
borns, maternal methadone use prolongs 
QTc in infants in the first two days of their 
life, which is similar to the effects of metha-
done in adults (Nekhayeva et al., 2005; 
Parikh et al., 2011; Philipp et al., 2003; 
Villain et al., 1992). Hussain and Ewer 
(2007) presented a case of significant QT in-
terval prolongation in a neonate secondary to 
use of methadone by its mother. They 
showed that methadone, even in low mater-
nal doses, could cause conduction disturb-
ances in neonates. Parikh et al. (2011), com-
pared QTc interval in infants born to mothers 
on MMT with healthy controls. In the first 
group, QTc interval was significantly pro-
longed on days 1 and 2 of life. On days 4 and 
7, this increase was no longer present. It was 
concluded that maternal methadone therapy 
could prolong QTc in newborns and infants 
and put them at risk of cardiac rhythm dis-
turbances. Wheeler and Tobias (2006) re-
ported a case of methadone use in an infant 
whose heart rate decreased from 130-140 
beats/min to 80-90 beats/min after the first 
dose of methadone concluding that metha-
done had the same structure as calcium 
channel antagonists and led to bradycardia. 
As previously shown, elimination of me-
thadone from the body is slower in neonates 
compared with older children or adults. Me-
thadone is greatly lipid-soluble and highly 
protein-bound which is responsible for its 
larger volume of distribution and slower 
clearance. In fact, neonates have more lipid 
tissue and higher plasma protein concentra-
tions, which may change drug distribution 
and metabolism significantly (Chana and 
Anand, 2001). 
 
Use of methadone in children 
Methadone is currently more available in 
American houses which predisposes the tod-
dlers to its toxicity (Boyer et al., 2010). Opi-
oids are often used as sedatives in pediatric 
intensive care unit (PICU). Administration of 
methadone in PICU was first reported in 
1990 to prevent opioid withdrawal (Siddappa 
et al., 2003); however, it is now increasingly 
being administered as a treatment of chronic 
pain syndromes in children (Boyer et al., 
2010; Wood et al., 2002). There have also 
been case reports of methadone use to pre-
vent abstinence syndrome in the PICU and 
for the treatment of burns in children (Davies 
et al., 2008). The factors that have made 
methadone attractive in pediatrics include its 
comfortable oral use, longer half-life, and 
ease in calculation of the dose because of its 
equivalent potency with morphine (Siddappa 
et al., 2003).  
Although methadone use is beneficial in 
pediatrics, it has known toxic effects on car-
diac conduction that may worsen medical 
problems appearing in puberty (Boyer et al., 
2010; Katchman et al., 2002). Children are 
particularly susceptible to effects from QT 
prolongation (Boyer et al., 2010). Yet, in 
some cases, there is a transient and benign 
QT prolongation in apparently healthy chil-
dren (Hussain and Ewer, 2007). Pediatric 
methadone toxicity in children has been 
shown to cause peripheral vasodilation (pre-
disposing to orthostatic hypotension), sinus 
bradycardia, and cerebrovascular vasodilata-
tion (due to decreased sensitivity of the res-
piratory center to CO2 leading to an in-
creased PCO2), which can increase intracra-
nial pressure. No arrhythmias such as Tdp 
are described (Guay, 2009). 
 
Animal studies 
In animals, opioids are used as part of 
balanced anesthetic methods and for treating 
pain (Maiante et al., 2009; Ingvast‐Larsson 
et al., 2010). However, there is little infor-
mation about the safety and analgesic effica-
cy of methadone in veterinary medicine 
(Maiante et al., 2009). 
There are several studies about pharma-
cology of methadone in dogs (Ingvast‐
Larsson et al., 2010, 2007; Maiante et al., 
2009; Pimentel and Mayo, 2008). Elimina-
tion of methadone in canines is different 
from humans. Methadone is rapidly elimi-
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nated from the animal body because of a 
high clearance rate. The oral bioavailability 
is low in dogs with half-lives of 1.75-6 hours 
and 2-12 hours following intravenous (IV) 
and subcutaneous (SC) administration, re-
spectively (Ingvast‐Larsson et al., 2010). 
Methadone causes cardiovascular depression 
in dogs. Maiante et al. (2009), compared the 
effect of methadone and morphine in dogs. 
Methadone was concluded to induce depres-
sant dose-related cardiovascular changes in 
conscious dogs. In fact, methadone causes a 
dose-dependent decrease in heart rate and 
cardiac index as well as increase in the sys-
temic vascular resistance index. Garofalo 
and colleagues (2009) compared the cardio-
respiratory and neuro-hormonal effects of 
methadone in conscious and in isoflurane-
anaesthetized dogs. Methadone induced dys-
phoria in all conscious dogs and significantly 
increased mean arterial pressure, catechola-
mines, and vasopressin concentrations. Dur-
ing anesthesia, in addition to greater decreas-
es in heart rate and cardiac index, methadone 
induced apnea and mechanical ventilation 
was necessary in all dogs. In anaesthetized 
animals, methadone administration signifi-
cantly increased vasopressin concentrations 
and systemic vascular resistance index, while 
mean arterial pressure did not differ from 
baseline. In contrast, isoflurane enhanced the 
intensity of the cardio-respiratory changes 
induced by methadone. Vasoconstrictive re-
sponses associated with methadone did not 
appear to be induced by vasopressin. In-
creases in circulating catecholamines, possi-
bly caused by dysphoric reactions to metha-
done administration, may attenuate the nega-
tive chronotropism and the decrease in cardi-
ac index observed when methadone is ad-
ministered to conscious dogs. 
Methadone use increases plasma vaso-
pressin up to 40 times in dogs and goats 
(Garofalo et al., 2012; Ingvast‐Larsson et al., 
2010; Pimentel and Mayo, 2008). Vasopres-
sin released by the pituitary stimulates V1a 
receptors leading to peripheral vasocon-
striction. This has been suggested as the pos-
sible responsible cause of systemic vasocon-
striction detected after methadone admin-
istration (Garofalo et al., 2012). 
It was shown that high methadone doses 
affected cardiac function in guinea pig heart 
cell preparations. Methadone strengthens the 
inotropic heart response to sympathetic 
stimulation in a dose-dependent manner that 
can be antagonized by increased extracellular 
calcium concentration (Anguera et al., 2008; 
Gil et al., 2003; Lamont and Hunt, 2006). 
At concentrations of ≥ 10 μM in isolated 
sheep Purkinje fibers, methadone decreases 
the maximum rate of depolarization and in-
creases the duration of action potential. High 
concentrations of methadone can affect sev-
eral parameters of cardiac function through a 
mechanism different from opioid receptor 
stimulation causing QT prolongation (Gil et 
al., 2003). 
 
Treatment 
The treatment of methadone cardiotoxici-
ty depends on patients' signs and symptoms. 
The asymptomatic or symptomatic prolonga-
tion of QTc interval are differently managed 
(Deamer et al., 2001). In the case of prolon-
ged QT syndrome and Tdp, predisposing 
factors should be corrected and use of special 
medications should be evaluated (Nair et al., 
2008). If an increased serum methadone con-
centration is the reason of cardiotoxicity, it is 
advised to lower the methadone dose (Krook 
et al., 2004). Methadone-induced Tdp asso-
ciated with hypokalemia should be treated 
with IV potassium. Magnesium administra-
tion is suggested for those with QTc prolon-
gation even if the serum concentration of Mg 
is normal (Deamer et al., 2001; Zipes et al., 
2006). Since R-isomer less inhibits the 
hERG channel, substitution of (R,S)-metha-
done by (R)-methadone reduces the QTc in-
terval value (Ansermot et al., 2010). If the 
patient has a QTc ≥ 500 msec, it is reasona-
ble to change methadone with another drug 
and refer the patient to a cardiologist 
(Somberg and Molnar, 2002). The proper al-
ternatives include buprenorphine, naltrexone, 
or slow-release oral morphine (Deamer et al., 
2001; Kastelic et al., 2008). 
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Buprenorphine is a partial μ-agonist and 
a κ-antagonist effective at lowering the use 
of opioids among opiate-addicted people. No 
report of QT prolongation has been given 
with buprenorphine. Thus, it is a good alter-
native for methadone in opiate dependency 
and chronic pain (Esses et al., 2008). During 
the first years of methadone and buprenor-
phine administration, death rate of these two 
drugs was compared concluding that bu-
prenorphine was associated with a much 
lower mortality rate than methadone (Perrin‐
Terrin et al., 2011). A 56-year-old man with 
syncope and Tdp secondary to methadone 
has been presented in the literature in whom, 
after transition to buprenorphine, QT interval 
normalized and ventricular arrhythmias re-
solved (Esses et al., 2008). De Jong and De 
Ruiter (2013) introduced a 52-year-old man 
who was admitted to the hospital due to Tdp. 
He had used methadone two days earlier. 
Buprenorphine was substituted and QTc nor-
malized after two weeks. In a cross-sectional 
study by Fanoe and colleagues (2007), meth-
adone was associated with long QT interval, 
but there was not any association between 
buprenorphine and QTc interval. Stallvik et 
al. (2013), found that buprenorphine was a 
suitable alternative for methadone regarding 
the risk of QTc prolongation. 
In cases of recurrent methadone-
associated Tdp whose medication cannot be 
changed, permanent pacing with the use of 
defibrillator Implantable Cardioverter Defib-
rillator (ICD) can be done (Miller et al., 
2011). Patel and coworkers (2008) reported 
that from their eight patients undergoing this 
treatment, three who continued taking meth-
adone after ICD placement received shocks 
for Tdp within the 2-year follow-up. The 
procedure was therefore heralded as poten-
tially lifesaving for people with a history of 
Tdp who continued to take methadone. 
However, one of the eight patients died be-
cause of unknown causes, and two suffered 
serious peri-operative complications (peri-
cardial tamponade and device infection). 
Another choice of treatment in these pa-
tients with limitations in switching the drug 
or those at risk of device infection is left car-
diac sympathetic denervation (LCSD). This 
method is a preganglionic denervation with 
antifibrillatory effects and emerging as an 
important adjunctive therapy in the man-
agement of ventricular arrhythmias. Miller et 
al. (2011), introduced the first case of drug-
induced QT prolongation successfully man-
aged with LCSD.  
The efficacy of oral activated charcoal 
for adsorption of drugs and poisons has been 
widely described in the literature. Activated 
charcoal is helpful if administrated within 1–
2 hours after ingestion. Since routine use of 
AC is discouraged, it is important to consider 
the risks and benefits of AC on a drug-by-
drug basis (Chyka et al., 2005; Khosrojerdi 
et al., 2013). 
 
Recommendations 
MMT personnel, patients, and their fami-
lies need to be better informed about the 
manifestations of methadone poisoning and 
their suitable management to reduce the 
morbidity and mortality rates associated with 
methadone (Caplehorn and Drummer, 2002). 
It is recommended that methadone patients 
and their families be evaluated regarding any 
history of syncope, sudden death, structural 
heart disease, or any other cardiac-related 
signs and symptoms. In addition, physicians 
should seek for the use of agents inhibiting 
CYP3A4 or CYP2B6 enzymes especially 
cimetidine, ciprofloxacin, erythromycin, 
clarithromycin, fluvoxamine, and pink 
grapefruit or Seville orange juice (Anderson 
and Kearney, 2000; Boyer et al., 2010). Cli-
nicians prescribing methadone should also 
notice the wide inter-individual variability in 
the rate of methadone metabolism and the 
small difference between its therapeutic and 
toxic doses (Backmund et al., 2001; Mehr-
pour et al., 2013). 
Before administration of methadone, 
conducting cardiovascular screening is rea-
sonable and cheap. Screening includes echo-
cardiography (to exclude heart disease) and 
check of possible electrolyte imbalances 
(Justo et al., 2006). ECG assessment might 
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be considered in new patients with history of 
known heart disease or recent symptoms like 
unexplained seizures, exertional chest pain 
or discomfort, exertional dyspnea, unex-
plained syncope or heart palpitations 
(Maremmani et al., 2004). QT interval calcu-
lation should be conducted before prescrip-
tion of methadone. The ECG should be 
checked at regular intervals. This is especial-
ly important within days of starting metha-
done therapy (Krook et al., 2004); the ECG 
should be obtained before initiation of meth-
adone and 4-7 days after its initiation. Addi-
tional ECGs are recommended 4-7 days after 
increase of dosage, when patients have un-
explained syncope or seizures, and/or when 
there are changes in condition or therapy, 
which increase the risk of arrhythmia 
(Deamer et al., 2001). ECG screening may 
not be possible in all patients on MMT. Alt-
hough the screening procedure itself is not 
expensive, interpretation of ECGs by cardi-
ologists may be expensive (Fareed et al., 
2010). Automated measurement of the QT 
interval may be used but is not accurate or 
trustworthy enough to be applied (Calver et 
al., 2012; Isbister et al., 2009; Malik and 
Camm, 2001). 
In order to better show the effect of 
methadone on the QT interval over a 24-hour 
period, high-resolution digital holter record-
ers are the most accurate tools to measure the 
QT with modern algorithms. Calver et al. 
(2012), found that this method could make a 
risk assessment; however, this still required 
manual interpretation of the QT using on-
screen magnification and calipers (Hnatkova 
et al., 2006). 
 
CONCLUSION 
Methadone has become popular in the 
treatment of opioid addiction and pain be-
cause of its special pharmacokinetic and 
pharmacodynamic characteristics. But, pa-
tients are at risk of methadone cardiotoxicity. 
Effectiveness of methadone in the treatment 
of pain and addiction should be weighed 
against these adverse effects and physicians 
should consider the ways to minimize these 
undesirable effects. 
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